TapewireFind a company

person · Reporting owner

Fairmount Healthcare Fund II GP LLC

Disclosed activity across 1 company

Tapewire entity
47598
SEC CIK
0001830382

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Viridian Therapeutics, Inc.\DEVRDN · Entity 4316Director · 10% ownerMay 11, 2026May 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Viridian Therapeutics, Inc.\DE

Report date May 11, 2026 · Filed May 13, 2026

Jointly reported with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Fairmount Healthcare Fund II L.P.5,090,928 Reported balance After 2026-05-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2026-05-11 · Purchase · Acquired 1,176,470 · Balance 5,090,928

F1: Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 11, 2026 Filed May 13, 2026 20:31 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 PurchaseCommon Stock 1,176,470 $17.00 $19,999,990.00
Disclosure

SEC source: 0001104659-26-060294 · tm2614357-1_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 5,090,928

F1 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
October 23, 2025 Filed Oct 27, 2025 20:30 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 PurchaseCommon Stock 454,545 $22.00 $9,999,990.00
Disclosure

SEC source: 0001104659-25-102606 · tm2529526-1_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 3,914,458

F1 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
June 10, 2025 Filed Jun 11, 2025 21:00 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionStock Option (Right to Buy) · Derivative 12,500 $0.00 Strike: $12.31 $0.00
Disclosure

SEC source: 0001104659-25-058580 · tm2517665d1_4seq1.xml · derivative · entry 4

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Peter Harwin

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires 2025-06-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · ownership.direct: Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin held options received as director compensation from the Issuer for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from such options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

Read SEC document
June 10, 2025 Filed Jun 11, 2025 21:00 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionCommon Stock 12,500 $12.31 $153,875.00
Disclosure

SEC source: 0001104659-25-058580 · tm2517665d1_4seq1.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 3,459,913

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
June 09, 2025 Filed Jun 11, 2025 21:00 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionStock Option (Right to Buy) · Derivative 1,600 $0.00 Strike: $7.80 $0.00
Disclosure

SEC source: 0001104659-25-058580 · tm2517665d1_4seq1.xml · derivative · entry 3

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Peter Harwin

Disclosed balance after: 0

Underlying: Common Stock · 1,600 shares

Expires 2025-06-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Beginning on October 27, 2020, the option vested monthly over a three-year period, subject to Peter Harwin's continued service to the Issuer. Mr. Harwin, a Managing Member of Fairmount and Fairmount GP II, served on the Issuer's Board of Directors through March 10, 2025.

F3 · ownership.direct: Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin held options received as director compensation from the Issuer for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from such options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

Read SEC document
June 09, 2025 Filed Jun 11, 2025 21:00 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 Exercise / conversionCommon Stock 1,600 $7.80 $12,480.00
Disclosure

SEC source: 0001104659-25-058580 · tm2517665d1_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 3,447,413

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
September 13, 2024 Filed Sep 18, 2024 01:00 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 PurchaseCommon Stock 1,600,000 $18.75 $30,000,000.00
Disclosure

SEC source: 0001104659-24-100769 · tm2424272-1_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 3,445,813

F1 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
March 28, 2024 Filed Apr 1, 2024 18:32 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 OtherSeries A Non-Voting Convertible Preferred Stock · Derivative 21,999 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-039599 · ownership.xml · derivative · entry 4

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 133,191

Underlying: Common Stock · 1,466,673 shares

Expires not disclosed

F4 · derivative.exercise_price: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.

F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F4 · derivative.exercise_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.

F4 · derivative.expiration_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.

F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
March 28, 2024 Filed Apr 1, 2024 18:32 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 OtherSeries A Non-Voting Convertible Preferred Stock · Derivative 21,999 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-039599 · ownership.xml · derivative · entry 3

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund LP

Disclosed balance after: 0

Underlying: Common Stock · 1,466,673 shares

Expires not disclosed

F4 · derivative.exercise_price: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.

F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F4 · derivative.exercise_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.

F4 · derivative.expiration_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
March 28, 2024 Filed Apr 1, 2024 18:32 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 OtherCommon Stock 5,859 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-039599 · ownership.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 1,845,813

F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F1 · price: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
March 28, 2024 Filed Apr 1, 2024 18:32 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 OtherCommon Stock 5,859 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-039599 · ownership.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund LP

Disclosed balance after: 0

F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F1 · price: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").

F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
January 22, 2024 Filed Jan 24, 2024 18:44 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 PurchaseCommon Stock 476,190 $21.00 $9,999,990.00
Disclosure

SEC source: 0000950170-24-007123 · ownership.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner · See Remarks

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner · See Remarks

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 1,839,954

F1 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 21:05 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 GrantSeries B Non-Voting Convertible Preferred Stock · Derivative 48,463 $825.37 $40,000,129.24
Disclosure

SEC source: 0000950170-23-057692 · ownership.xml · derivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner · See Remarks

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II LP

Disclosed balance after: 48,463

Underlying: Common Stock · 3,231,028.21 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.

F2 · shares: The shares of Series B non-voting convertible preferred stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended.

F1 · derivative.exercise_date: Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.

F1 · derivative.expiration_date: Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.

F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and Series B non-voting convertible preferred stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
August 17, 2022 Filed Aug 19, 2022 16:32 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 PurchaseCommon Stock 425,531 $23.50 $9,999,978.50
Disclosure

SEC source: 0001104659-22-092992 · tm2224209-1_4seq1.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner · See Remarks

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · 10% owner

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 1,363,764

F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
September 21, 2021 Filed Sep 23, 2021 09:30 UTC Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 PurchaseCommon Stock 909,000 $11.00 $9,999,000.00
Disclosure

SEC source: 0000899243-21-037255 · doc4.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 938,233

F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
October 30, 2020 Filed Oct 30, 2020 11:53 UTC Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 PurchaseSeries A Non-Voting Convertible Preferred Stock · Derivative 28,843 $465.96 $13,439,684.28
Disclosure

SEC source: 0000899243-20-029904 · doc4.xml · derivative · entry 4

Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 111,192

Underlying: Common Stock · 28,483,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F3 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
October 30, 2020 Filed Oct 30, 2020 11:53 UTC Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 PurchaseSeries A Non-Voting Convertible Preferred Stock · Derivative 5,494 $465.96 $2,559,984.24
Disclosure

SEC source: 0000899243-20-029904 · doc4.xml · derivative · entry 3

Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Fairmount Healthcare Fund LP

Disclosed balance after: 21,999

Underlying: Common Stock · 5,494,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F3 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F1 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund LP ("Fund I"). They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
October 27, 2020 Filed Oct 29, 2020 11:30 UTC Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 OtherSeries A Non-Voting Convertible Preferred Stock · Derivative 82,349 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-029660 · doc4.xml · derivative · entry 4

Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 82,349

Underlying: Common Stock · 82,349,000 shares

Expires not disclosed

F5 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion

F2 · kind: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock.

F2 · price: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock.

F5 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion

F5 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion

F4 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
October 27, 2020 Filed Oct 29, 2020 11:30 UTC Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 OtherSeries A Non-Voting Convertible Preferred Stock · Derivative 16,505 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-029660 · doc4.xml · derivative · entry 3

Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Fairmount Healthcare Fund LP

Disclosed balance after: 16,505

Underlying: Common Stock · 16,505,000 shares

Expires not disclosed

F5 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion

F1 · kind: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock.

F1 · price: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock.

F5 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion

F5 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion

F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
October 27, 2020 Filed Oct 29, 2020 11:30 UTC Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 OtherCommon Stock 438,502 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-029660 · doc4.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 438,502

F2 · kind: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock.

F2 · price: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock.

F4 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document
October 27, 2020 Filed Oct 29, 2020 11:30 UTC Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 OtherCommon Stock 87,891 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-029660 · doc4.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks

Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Fairmount Healthcare Fund LP

Disclosed balance after: 87,891

F1 · kind: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock.

F1 · price: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock.

F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.